Baird maintains Aramark at Outperform, lowers price target to $65 from $69

Baird kept its Outperform rating on Aramark but reduced its price target to $65 from $69, a 5.8% decrease. This implies a 17.4% upside from the Nov 16 close of $55.37.

Original reporting
Published Nov 17, 2026, 11:36 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 11:45 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Baird maintains Aramark at Outperform, lowers price target to $65 from $69 — source image
Decision brief

The 30-second read

$ARMKNeutralLow
01

Why it matters

A lower target can influence near-term sentiment and positioning, but without new operational or financial data it is unlikely to drive a major repricing by itself.

02

Market read

Traders may adjust expectations for Aramark’s upside based on the revised target, but the unchanged rating limits urgency.

03

What to watch

Price-target cuts can be less informative than changes to earnings estimates or guidance, which are not provided in this article.

Relevance 4/10Novelty 3/10Timing: as of the analyst note publication time

Background

The piece is an analyst note update from Baird, not a company disclosure.

Company-level read

Ticker impact

$ARMKNeutralMedium confidence
Context

Baird maintained Aramark at Outperform and cut its price target to $65 from $69, signaling a revised valuation view.

Expected impact

Likely mild downward pressure or limited upside as the market digests the lower target, offset by the unchanged Outperform rating.

Evidence & confidence

The article provides only an analyst price-target change with no new company fundamentals; unchanged rating reduces the immediate bearishness.

Market effects

Minimal, since this is a single-name analyst target adjustment without new sector-wide information.

None indicated.

None indicated.

Counterpoint

The unchanged Outperform rating could still support dip-buying, with the lower target reflecting valuation discipline rather than deteriorating fundamentals.

Key entities

  • Aramark

    Subject of the analyst action: maintained Outperform, lowered price target to $65 from $69.

Related articles

$ARMKMed

Aramark Q4 2026 Earnings Call Summary

Aramark reported record annualized gross new client wins of $1.9 billion, a 97% client retention rate, and launched Aramark Nexus. The company reduced its leverage ratio to 2.7x, enabling a $1 billion share repurchase program and a 17% dividend increase. For fiscal 2027, Aramark projects $500 million in revenue from Nexus, 9-10% organic revenue growth, and 15-19% adjusted operating income growth. Management highlighted supply chain efficiencies and mitigating inflation impacts.

$ARMKMed

Aramark (ARMK) Q4 2026 Earnings Call Transcript

Aramark (ARMK) reported Q4 2026 revenue of $20.1B, up 10% YoY, with U.S. and international organic growth of 8% and 12%, respectively. Adjusted EPS grew 21% on a constant currency basis. The company announced a $1B share repurchase program and a 17% dividend increase. Key segments like Collegiate Hospitality and Healthcare Plus drove growth. Aramark Nexus contributed 1% to organic revenue growth, scaling premium hospitality services.

$ARMKHigh

Why is Aramark stock sliding today?

Aramark (ARMK) shares fell 4.7% pre-market after reporting Q4 2026 results that missed estimates, with adjusted EPS at $0.71 vs. $0.75 and revenue at $5.29B vs. $5.30B. The company's fiscal 2027 guidance also fell short of expectations. Despite a 25% YoY EPS increase and 4.8% revenue growth, the stock dropped due to broader market pressures and the earnings miss.